An Open Label Study of the Chronic and Acute Effects of Pitavastatin on Monocyte Phenotype, Endothelial Dysfunction and HDL Atheroprotective Function in Subjects With Metabolic Syndrome (CAPITAIN)

Trial Profile

An Open Label Study of the Chronic and Acute Effects of Pitavastatin on Monocyte Phenotype, Endothelial Dysfunction and HDL Atheroprotective Function in Subjects With Metabolic Syndrome (CAPITAIN)

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jul 2013

At a glance

  • Drugs Pitavastatin (Primary)
  • Indications Atherosclerosis; Metabolic syndrome
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms CAPITAIN
  • Sponsors Kowa Research Institute
  • Most Recent Events

    • 16 May 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top